Do you have any of your baby teeth or are you a parent who has kept your child's baby teeth? Are you a young adult or a parent of a child age 25 or under? Did you know scientists can learn all about different medications, foods, and environmental exposures in a child's early life from their teeth? You may be able to take part in a research study to learn what factors increase children's risk of developing EoE (eosinophilic esophagitis)! We are looking for children and young adults (age 0-25) with or without EoE to volunteer. Compensation will be provided.

We want to learn if a new, minimally invasive device can collect and detect tissue surface cells from the esophagus without sedation.

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is doing this study because they want to learn more about eosinophilic gastrointestinal disorders (EGIDs).

We are doing a survey to learn about swallowing problems, like trouble swallowing food or drinks, in college students. The survey asks questions to see how often these problems happen and what students do to manage them. This will help us understand more about these issues and raise awareness so students can get help if needed.

Assess the clinical response to treatment with mirikizumab among patients with chronic inflammatory conditions of the pouch using standardized outcome assessments.

To create a biorepository for future research studies to better improve patient treatment in care for patients with liver cancer and liver diseases

1) Assess and compare adherence to IV and subcut vedolizumab maintenance therapy in patients with IBD using a novel remote monitoring system. 2) Assess symptom response to vedolizumab post induction (week 6-8) and during maintenance therapy (week 26) using a novel remote monitoring system. 3) Assess time to response to vedolizumab during induction (weeks 0-6) using a novel remote monitoring system.

The primary endpoint for this study is subjects achieving either a decrease in Urgency Numeric Rating Scale (NRS) score of ≥ 2 points, or a decrease in score of ≥ 30%, at 12 weeks. Success is defined as ≥ 50% of enrolled subjects meeting the primary endpoint.

The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis.

The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease.